Loading...
•
Sep 30, 2022
Personalis Q3 2022 Earnings Report
Reported a decrease in revenue, but an increase in biopharma revenue, excluding VA MVP.
Key Takeaways
Personalis reported a revenue of $14.9 million for Q3 2022, a decrease compared to Q3 2021. However, revenue from biopharma and other customers, excluding the VA MVP, increased by 73%. The company continues to focus on strategic priorities and collaborations to advance precision oncology.
Reported quarterly revenue of $14.9 million in Q3 2022, compared to $22.3 million in Q3 2021.
Revenue from biopharma and other customers, excluding the VA MVP, increased by 73% to $14.9 million.
Launched research collaborations with BC Cancer and Duke University using NeXT Personal™ for MRD detection and tracking.
Appointed Christopher Hall as SVP to lead the company’s Diagnostic Business.
Forward Guidance
Personalis expects full year 2022 total company revenue to be in the range of $63.0 million to $64.0 million. Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.5 million to $56.5 million. Net loss is expected to be in the range of $111.0 million to $114.0 million.
Positive Outlook
- Total company revenue is expected to be in the range of $63.0 million to $64.0 million
- Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.5 million to $56.5 million
Challenges Ahead
- Net loss is expected to be in the range of $111.0 million to $114.0 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...